Donna Cutillo is a highly accomplished biopharmaceutical executive with over two decades of experience in business development, corporate strategy, alliance management, and strategic transactions within the life sciences sector. She currently serves as the Chief Business Officer at Kymera Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins. In her role, Donna is responsible for leading Kymera's business development, corporate strategy, and alliance management functions. Her expertise lies in identifying and executing strategic partnerships, licensing deals, and collaborations that drive innovation and growth. Prior to Kymera, Donna held significant leadership positions at Celgene Corporation (now part of Bristol Myers Squibb) for over a decade, including Corporate Vice President and Global Head of Business Development. During her tenure at Celgene, she was instrumental in numerous high-value transactions that shaped the company's portfolio, particularly in oncology and immunology. Donna is recognized for her strategic thinking, strong negotiation skills, and her ability to build and lead high-performing teams to achieve corporate objectives.
Donna Cutillo's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:
As Chief Business Officer at Kymera Therapeutics, spearheaded key strategic collaborations and partnerships, leveraging the company's targeted protein degradation platform to advance novel drug candidates and expand its pipeline. For example, she was involved in securing major collaborations with companies like Sanofi and Vertex Pharmaceuticals.
During her extensive tenure at Celgene, played a pivotal role in numerous transformative business development deals, including significant M&A activities, licensing agreements, and strategic alliances that substantially contributed to Celgene's growth into a global biopharmaceutical leader.
Consistently demonstrated a strong ability to identify and cultivate strategic partnerships that accelerate the development and commercialization of innovative therapies for patients with serious diseases, particularly in oncology and inflammation.
Recognized for her leadership in building and mentoring successful business development and alliance management teams, fostering a collaborative and results-oriented environment.
Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Richline Group, a wholly-owned subsidiary of Berkshire Hathaway, is a leading global jewelry manufacturer, distributor, and marketer. Established in 2007, the company leverages its extensive industry expertise and a diverse portfolio of brands to provide a wide array of precious metal, gemstone, and diamond jewelry. Richline serves major retailers, department stores, and television shopping networks worldwide, focusing on design innovation, quality craftsmanship, and responsible sourcing. Their product categories span from bridal and fine fashion jewelry to licensed collections and private label programs.
Get verified emails, phone numbers, and LinkedIn profile details
Discover contacts with similar roles, seniority, or companies
Uncover insights like skills, work history, social links, and more
Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.
Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.
Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.
Thousands of companies, including, are just a search away.